Astellas Pharma and Seagen have reported positive topline data from the Phase Ib/II EV-103 clinical trial (KEYNOTE-869) Cohort K of Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) as first-line therapy for unresectable locally advanced or metastatic urothelial cancer (la/mUC) patients.
A randomised cohort, EV-103 Cohort K is analysing enfortumab vedotin alone or along with pembrolizumab as first-line therapy for unresectable la/mUC patients, ineligible for cisplatin-based chemotherapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the trial findings from this cohort, the combination therapy offered a confirmed objective response rate (ORR) per blinded independent central review (BICR) of 64.5%, the primary endpoint.
Astellas noted that the median duration of response (DOR) per BICR was not attained.
Rash maculo-papular, anaemia, lipase increased and urinary tract infection among others were the most commonly reported treatment-emergent adverse events Grade 3 or greater reported in over 5% of trial subjects.
These results are generally in line with priorly reported efficacy and safety data from the EV-103 dose-escalation cohort and expansion Cohort A.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAstellas Development Therapeutic Areas senior vice-president and head Ahsan Arozullah said: “Approximately half of patients with advanced urothelial carcinoma are ineligible for cisplatin-based chemotherapy.
“We intend to discuss Cohort K results with regulatory authorities as we seek to develop a new first-line treatment combination for these patients.”
Keytruda is an anti-PD-1 therapy of Merck.
Currently, Astellas, Seagen and Merck are analysing enfortumab vedotin plus pembrolizumab as part of a partnership, which includes three Phase III trials.
In May last year, Astellas and Seagen reported data from EV-201 and EV-103 trials where Padcev offered durable responses in locally advanced or metastatic urothelial cancer patients.
